In this week’s news roundup from Rheumatology Network, we talk with Dr. Chrstine Anastasiou, a rheumatologist with the University of California San Francisco who recently published a study in Arthritis Care and Research that finds significant improvements in mortality for hospitalized patients in the U.S. with systemic lupus, but there remains a high mortality rate among blacks and Hispanics with SLE, and, now among Asian/Pacific Islanders with the condition. Learn more in this interview.
A few weeks after a camping trip in Connecticut, a 24-year-old woman went to her local urgent care center with flu-like symptoms of myalgia, arthralgias, headache, and fever. She reported having an annular lesion on her leg shortly after the trip. Can you diagnose this patient?
Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.
In this slideshow, we highlight some presentations from EULAR 2020 we thought would interest you. The list includes a study that shows primary Sjogren’s syndrome affects men as well, and it highlights findings from a study that shows voclosporin was effective in treating lupus neprhitis in Latinas, a group disproportionately affected by the condition. More in this slideshow.
Asian countries regularly see higher rates of SLE prevalence globally.
Dr. Gregg Silverman said identification of Ruminococcus gnavus could allow earlier diagnosis of lupus nephritis.
A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.
In this week's Rheumatology Network news roundup, we highlight an interview we conducted with Brian LaMoreaux, M.D., M.S., a medical director at Horizon Therapeutics and a volunteer clinical rheumatologist with CommunityHealth in Chicago. In this interview, he shares his experience as a rheumatologist in a community where healthcare is not always easy to come by.
Outcomes for patients with lupus nephritis, which can lead to irreversible renal impairment, can be improved with better measures to evaluate risk and detect early disease, along with new treatments, say researchers writing in Nature Reviews Rheumatology.
This week, the National Institutes of Health issued treatment guidelines for the management of COVID-19. It does not include the use of pharmaceutical agents for pre or post-exposure prophylaxis, including hydroxychloroquine, except for within the confines of a clinical trial. This comes as good news to the rheumatology community. More in this article.
The international registry that was created in March to track rheumatology patients who have contracted COVID-19, has released data from the first 110 cases from six continents.
A 16-year-old African American girl reports sudden erythema covering her nose, cheeks, and upper back. Can you diagnose this patient?
The rheumatology community has expressed concerns about the use of hydroxychloroquine sulfate for COVID-19 because the drug is used to treat lupus patients and is already in short supply. The FDA has taken steps to redistribute the drug to hospitals for COVID-19 patients despite the lack of extensive clinical trials testing.
David Karp, MD, PhD, president-elect of ACR discusses what an appropriate hydroxychloroquine trial would look like, alternate treatment options, and how rheumatology experts should approach their patients during this time.
Patients with systemic lupus erythematosus depend on hydroxychloroquine to control disease activity, but demand for this drug, which was already in short supply, has spiked since President Trump championed its use for COVID-19 patients. The American College of Rheumatology has responded by issuing a series of recommendations. Learn more in this article.
Geeta Nayyar, MD, MBA, discusses how hydroxychloroquine and chloroquine affect patients with arthritis and how it differs for those with coronavirus.
Visceral fat appears to be associated with an increased risk of musculoskeletal and widespread pain, according to researchers writing this week in Arthritis and Rheumatology. Plus, a small study shows promise in a new treatment for a rare form of pediatric lupus. This and more news in today's rheumatology news roundup.
In a new study, investigators show belimumab as a treatment could normalize or stabilize proteinuria is patients with lupus nephritis.
In patients with moderate to severe systemic lupus erythematosus (SLE), anifrolumab (AstraZeneca) was superior to placebo for improving overall disease activity, skin disease and oral corticosteroid tapering, say researchers writing in the New England Journal of Medicine.
Anifrolumab, a potential new treatment for systemic lupus erythematosus (SLE), was given a second look in a clinical trial published in the New England Journal of Medicine this month. This time, the results look promising. Learn more about the trial in this slideshow.
In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.
2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
A large proportion of patients with systemic lupus erythematosus (SLE) have been inappropriately prescribed opioids, researchers reported recently in the Morbidity and Mortality Weekly Report.
Richard Furie, MD, chief of the division of rheumatology with Norwell Health, discusses the results of a phase 2 trial examining obinutuzumab for lupus nephritis.
